AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$ACOG

Opaleye Management Inc. purchased $1.1M of ACOG (indirect holdings)

Opaleye Management Inc. purchased 123,918 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.57 ($8.40–$8.70, $1.06M total) across 4 trades over 2026-09-14 to 2026-09-16.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Sep 16, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The filing adds a new data point on ownership structure, which may affect short‑term liquidity and price dynamics.

02

Market read

A primary Form 4 filing revealing a $1M insider purchase by a major shareholder, offering a modest trading signal for ACOG.

03

What to watch

Potential upcoming financing or strategic actions not disclosed could influence the stake's significance.

Relevance 7/10Novelty 8/10Timing: filed Sep 16, 2026

Background

Alpha Cognition (ACOG) is a micro‑cap AI technology firm. Insider transactions are closely watched for signals of management confidence.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management, a 10% owner, purchased 123,918 shares of Alpha Cognition for $1.06M, increasing its stake to 3,172,141 shares.

Expected impact

Modest upward pressure as the market digests the new stake increase.

Evidence & confidence

A $1M purchase by a 10% owner is material for a micro‑cap, but the amount is modest relative to typical float, limiting impact.

Market effects

Sector

Limited; reflects insider confidence in Alpha Cognition's AI/tech positioning.

Regional

None; company is US‑listed.

Global

Low; isolated to the ticker.

Counterpoint

What could challenge this read

The purchase could be a defensive move to maintain control rather than a bullish signal.

Key entities

  • Insider Investor
    Opaleye Management Inc.

    10% owner of Alpha Cognition, executed the purchase.

  • Company
    Alpha Cognition Inc.

    Issuer of the shares purchased.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min